173 related articles for article (PubMed ID: 35347903)
1. Drug Prescription Patterns During Initial Treatment of Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia: A Study Based on Health Insurance Review and Assessment Database.
Lee JW; Kim JH
J Korean Med Sci; 2022 Mar; 37(12):e95. PubMed ID: 35347903
[TBL] [Abstract][Full Text] [Related]
2. Drug treatment patterns for the management of men with lower urinary tract symptoms associated with benign prostatic hyperplasia who have both storage and voiding symptoms: a study using the health improvement network UK primary care data.
Hakimi Z; Johnson M; Nazir J; Blak B; Odeyemi IA
Curr Med Res Opin; 2015 Jan; 31(1):43-50. PubMed ID: 25333647
[TBL] [Abstract][Full Text] [Related]
3. Prescription pattern of alpha-blockers for management of lower urinary tract symptoms/benign prostatic hyperplasia.
Moon HW; Yang JH; Choi JB; Bae WJ; Cho HJ; Hong SH; Lee JY; Kim SW; Park SH; Han K; Ha US
Sci Rep; 2018 Sep; 8(1):13223. PubMed ID: 30185936
[TBL] [Abstract][Full Text] [Related]
4. Drug adherence and clinical outcomes for patients under pharmacological therapy for lower urinary tract symptoms related to benign prostatic hyperplasia: population-based cohort study.
Cindolo L; Pirozzi L; Fanizza C; Romero M; Tubaro A; Autorino R; De Nunzio C; Schips L
Eur Urol; 2015 Sep; 68(3):418-25. PubMed ID: 25465970
[TBL] [Abstract][Full Text] [Related]
5. Mirabegron Vs Placebo Add-on Therapy in Men With Overactive Bladder Symptoms Receiving Tamsulosin for Underlying Benign Prostatic Hyperplasia: A Safety Analysis From the Randomized, Phase 4 PLUS Study.
Herschorn S; McVary KT; Cambronero Santos J; Foley S; Kristy RM; Choudhury N; Hairston J; Kaplan SA
Urology; 2021 Jan; 147():235-242. PubMed ID: 33045287
[TBL] [Abstract][Full Text] [Related]
6. Trends in medical management of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
Filson CP; Wei JT; Hollingsworth JM
Urology; 2013 Dec; 82(6):1386-92. PubMed ID: 24269224
[TBL] [Abstract][Full Text] [Related]
7. Medical Treatment of Benign Prostatic Hyperplasia.
Plochocki A; King B
Urol Clin North Am; 2022 May; 49(2):231-238. PubMed ID: 35428429
[TBL] [Abstract][Full Text] [Related]
8. Characteristics of men with untreated LUTS interested in over-the-counter tamsulosin.
Roehrborn CG; Lowe FC; Gittelman M; Wruck JM; Verbeek AE
Can J Urol; 2019 Aug; 26(4):9821-9828. PubMed ID: 31469636
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of a Fixed-Dose Combination Therapy of Tamsulosin and Tadalafil for Patients With Lower Urinary Tract Symptoms and Erectile Dysfunction: Results of a Randomized, Double-Blinded, Active-Controlled Trial.
Kim SW; Park NC; Lee SW; Yang DY; Park JK; Moon DG; Yang SK; Lee SW; Moon KH; Ahn TY; Kim SW; Park K; Min KS; Ryu JK; Son H; Jung J; Hyun JS
J Sex Med; 2017 Aug; 14(8):1018-1027. PubMed ID: 28760246
[TBL] [Abstract][Full Text] [Related]
10. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study.
Roehrborn CG; Siami P; Barkin J; Damião R; Major-Walker K; Nandy I; Morrill BB; Gagnier RP; Montorsi F;
Eur Urol; 2010 Jan; 57(1):123-31. PubMed ID: 19825505
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of tadalafil vs tamsulosin in lower urinary tract symptoms (LUTS) as a result of benign prostate hyperplasia (BPH)-open label randomised controlled study.
Singh I; Tk A; Gupta S
Int J Clin Pract; 2020 Aug; 74(8):e13530. PubMed ID: 32542854
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Mirabegron versus Placebo Add-On Therapy in Men with Overactive Bladder Symptoms Receiving Tamsulosin for Underlying Benign Prostatic Hyperplasia: A Randomized, Phase 4 Study (PLUS).
Kaplan SA; Herschorn S; McVary KT; Staskin D; Chapple C; Foley S; Cambronero Santos J; Kristy RM; Choudhury N; Hairston J; Schermer CR
J Urol; 2020 Jun; 203(6):1163-1171. PubMed ID: 31895002
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of a fixed-dose combination of solifenacin and oral controlled adsorption system formulation of tamsulosin in men with lower urinary tract symptoms associated with benign prostatic hyperplasia.
Nazir J; Heemstra L; van Engen A; Hakimi Z; Ivanescu C
BMC Urol; 2015 May; 15():41. PubMed ID: 25956727
[TBL] [Abstract][Full Text] [Related]
14. Current medical treatment of lower urinary tract symptoms/BPH: do we have a standard?
Silva J; Silva CM; Cruz F
Curr Opin Urol; 2014 Jan; 24(1):21-8. PubMed ID: 24231531
[TBL] [Abstract][Full Text] [Related]
15. A comparative randomized prospective study to evaluate efficacy and safety of combination of tamsulosin and tadalafil vs. tamsulosin or tadalafil alone in patients with lower urinary tract symptoms due to benign prostatic hyperplasia.
Singh DV; Mete UK; Mandal AK; Singh SK
J Sex Med; 2014 Jan; 11(1):187-96. PubMed ID: 24165272
[TBL] [Abstract][Full Text] [Related]
16. Actual medical management of lower urinary tract symptoms related to benign prostatic hyperplasia: temporal trends of prescription and hospitalization rates over 5 years in a large population of Italian men.
Cindolo L; Pirozzi L; Fanizza C; Romero M; Sountoulides P; Roehrborn CG; Mirone V; Schips L
Int Urol Nephrol; 2014 Apr; 46(4):695-701. PubMed ID: 24136187
[TBL] [Abstract][Full Text] [Related]
17. Treatment satisfaction with tadalafil or tamsulosin vs placebo in men with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH): results from a randomised, placebo-controlled study.
Oelke M; Giuliano F; Baygani SK; Melby T; Sontag A
BJU Int; 2014 Oct; 114(4):568-75. PubMed ID: 24612148
[TBL] [Abstract][Full Text] [Related]
18. Impact of early vs. delayed initiation of dutasteride/tamsulosin combination therapy on the risk of acute urinary retention or BPH-related surgery in LUTS/BPH patients with moderate-to-severe symptoms at risk of disease progression.
D'Agate S; Chavan C; Manyak M; Palacios-Moreno JM; Oelke M; Michel MC; Roehrborn CG; Della Pasqua O
World J Urol; 2021 Jul; 39(7):2635-2643. PubMed ID: 33337513
[TBL] [Abstract][Full Text] [Related]
19. Drug adherence and drug-related problems in pharmacotherapy for lower urinary tract symptoms related to benign prostatic hyperplasia.
Zabkowski T; Saracyn M
J Physiol Pharmacol; 2018 Aug; 69(4):. PubMed ID: 30552307
[TBL] [Abstract][Full Text] [Related]
20. A retrospective study of treatment persistence and adherence to α-blocker plus antimuscarinic combination therapies, in men with LUTS/BPH in the Netherlands.
Drake MJ; Bowditch S; Arbe E; Hakimi Z; Guelfucci F; Amri I; Nazir J
BMC Urol; 2017 May; 17(1):36. PubMed ID: 28532455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
